👉 Only 4 days left! Submit your abstract to the ESMO Sarcoma and Rare Cancers Congress 2027 (4-6 March, Lugano, Switzerland) by 24 November. Share your research with the rare cancers community.
🔗 ow.ly/1wBW5107I0i
#ESMORareCancers27 #esmomeetings
Artificial intelligence is increasingly being applied across #oncology, from pathology and imaging to genomics and electronic health records.
The ESMO Basic Requirements for AI-based Biomarkers in Oncology (EBAI) framework provides comprehensive guidance for the safe, trustworthy and effective integration of #AI-derived biomarkers into #CancerCare.
ow.ly/qLEi5107CYr
Join the upcoming #YO4YO HowTo Virtual Session with Guilherme Nader Marta (@GuiNaderMarta), Miriam Koopman and Anna Pellat for insights into conducting high-quality real-world evidence studies. #ESMOYOC
📅 23 November 2026, 15:00 CET
🔗 ow.ly/HYYm51065hO
ESMO welcomes the adoption of key reports in the @Europarl_EN on Horizon Europe and Europe’s Beating Cancer Plan: they reflect the Society’s calls to support the EU Cancer Mission and increase the EU’s research budget.
🔗 ow.ly/nv7H5107Xhk
#ESMOAI26: In an #InsightsbyESMO Opinion article, Maryellen Giger discusses the use of #DigitalOncology for #CancerScreening and detection and how newer #MedicalImaging and #CellfreeDNA advances could be leveraged to improve sensitivity.
🔗 ow.ly/WNw75107AEt
861
📣 Updated ESMO #ClinicalPracticeGuideline recommendations for oncogene-addicted metastatic #NSCLC highlight expanding range of targeted therapies available in 1L and resistance settings. #ESMOGuidelines #LungCancer #mNSCLC
🔗 ow.ly/c0Zz5107cu0
@HendriksLizza @APassaroMD @DrSanjayPopat @MartinReck2
#ESMOAI26: For treatment-naïve patients receiving highly emetogenic chemotherapy, #ImmersiveVR given prior to chemotherapy, alongside standard anti-emetic prophylaxis, significantly reduced chemotherapy-induced nausea and vomiting (#CINV) in an #RTC
#InsightsbyESMO ➡️ ow.ly/K05l5107hOj
👉 Are we defeating #CervicalCancer?
In this #ESMODeepDive, experts discuss pembrolizumab with chemoradiation, the role of PD-L1 status in immunotherapy decisions and treatment after progression.
ESMO members: ow.ly/ktm65106OVP
#ESMOOnAir
@Ilaria_Colombo_
#ESMOAI26: MultimodalAI foundation models could help interpret complex #CancerPatient data, supporting #ClinicalResearch and more informed decisions on further testing and treatment, as discussed by @_bunnech in an #InsightsbyESMO Opinion article
🔗 ow.ly/KmHs5107fTU
ESMO - Eur. Oncology retweeted
🆕 Article in press: Circulating tumor DNA to direct adjuvant immunotherapy across mismatch repair-deficient solid tumors @YJanjigianMD
🔗 doi.org/10.1016/j.annonc.202…
Last chance to register for #ESMOImmuno26.
Join leading experts in immuno-oncology and advanced therapies in London on 14-16 December.
⏰ Late Registration ends tomorrow, 18 Nov at 23:59 CET.
Register now:
ow.ly/1ITP5106OZf
#ESMOMeetings
#ESMOAI26: @ca_chung discusses study results showing how #multimodalAI frameworks can assist molecular tumour boards to make improved, treatment decisions for #CancerPatients with fewer errors and greater agreement between #MedicalProfessionals
🔗 ow.ly/g7jO5106Wza
#ESMOAI26: Ever more robust analyses of #BigData will lead to improved understanding of #CancerBiology and offer insights into #CancerEvolution dynamics, prognoses and #NovelTherapies, as discussed by Trevor Graham in an #InsightsbyESMO Opinion article
🔗ow.ly/p4Nz5106TOt
#ESMOAI26: For patients with advanced #NSCLC treated with #immunotherapy, adding #MedicalImaging from #PETscans to clinical data can improve #PFS prediction, according to a study using the DANTES #AI framework combining #CTscan, #PETscan and clinical data.
🔗 ow.ly/4pkk5106VX8
👏 Congratulations to the #ESMOMeritAward recipients at #ESMOAI26.
These young researchers are recognised for the scientific merit of their abstracts.
🔗 ow.ly/zkgf5106UGP
#HealthAI #CancerResearch
📢 ESMO has launched ESMO Artificial Intelligence and Oncology, a new peer-reviewed journal dedicated to the application of AI across #CancerResearch and care. The journal will support the evaluation, validation and implementation of AI in oncology through research and educational content.
🔗ow.ly/EbRr5106QjG
🙌 #ESMOAI26: M. Crispin Ortuzar, R. Fehrmann and J. Kather welcome you to the ESMO AI & Digital Oncology Congress 2026. Join experts shaping the future of AI and digital health in oncology, and gain the tools and knowledge to navigate this evolving landscape.
🔗 ow.ly/8fbA5105Grz
#esmomeetings
#ESMO26: Results from the phase II PACE-LUNG trial highlight the potential of ctDNA-guided treatment intensification in EGFR-mutated advanced #NSCLC, supporting further investigation of personalised treatment strategies.
➡️ ow.ly/fvU65105Nc9
#InsightsbyESMO
1
1,138
👏 Congratulations to Benjamin Bircher and Alexandra Marx, recipients of the 2025 ESMO Best Exam Award. Recognised during #ESMO26, they achieved the highest score among 887 candidates who took the #ESMOExamination in 2025.





















